1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical Stability and Storage Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical Stability and Storage Services Market, by Services
8.1.1 Stability
8.1.1.1. Market Revenue and Forecast
8.1.2. Storage
8.1.2.1. Market Revenue and Forecast
8.1.3. Cold
8.1.3.1. Market Revenue and Forecast
8.1.4. Non-cold
8.1.4.1. Market Revenue and Forecast
9.1. Pharmaceutical Stability and Storage Services Market, by Molecule
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast
10.1. Pharmaceutical Stability and Storage Services Market, by Mode
10.1.1. In-house
10.1.1.1. Market Revenue and Forecast
10.1.2. Outsourcing
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Services
11.1.2. Market Revenue and Forecast, by Molecule
11.1.3. Market Revenue and Forecast, by Mode
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Services
11.1.4.2. Market Revenue and Forecast, by Molecule
11.1.4.3. Market Revenue and Forecast, by Mode
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Services
11.1.5.2. Market Revenue and Forecast, by Molecule
11.1.5.3. Market Revenue and Forecast, by Mode
11.2. Europe
11.2.1. Market Revenue and Forecast, by Services
11.2.2. Market Revenue and Forecast, by Molecule
11.2.3. Market Revenue and Forecast, by Mode
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Services
11.2.4.2. Market Revenue and Forecast, by Molecule
11.2.4.3. Market Revenue and Forecast, by Mode
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Services
11.2.5.2. Market Revenue and Forecast, by Molecule
11.2.5.3. Market Revenue and Forecast, by Mode
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Services
11.2.6.2. Market Revenue and Forecast, by Molecule
11.2.6.3. Market Revenue and Forecast, by Mode
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Services
11.2.7.2. Market Revenue and Forecast, by Molecule
11.2.7.3. Market Revenue and Forecast, by Mode
11.3. APAC
11.3.1. Market Revenue and Forecast, by Services
11.3.2. Market Revenue and Forecast, by Molecule
11.3.3. Market Revenue and Forecast, by Mode
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Services
11.3.4.2. Market Revenue and Forecast, by Molecule
11.3.4.3. Market Revenue and Forecast, by Mode
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Services
11.3.5.2. Market Revenue and Forecast, by Molecule
11.3.5.3. Market Revenue and Forecast, by Mode
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Services
11.3.6.2. Market Revenue and Forecast, by Molecule
11.3.6.3. Market Revenue and Forecast, by Mode
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Services
11.3.7.2. Market Revenue and Forecast, by Molecule
11.3.7.3. Market Revenue and Forecast, by Mode
11.4. MEA
11.4.1. Market Revenue and Forecast, by Services
11.4.2. Market Revenue and Forecast, by Molecule
11.4.3. Market Revenue and Forecast, by Mode
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Services
11.4.4.2. Market Revenue and Forecast, by Molecule
11.4.4.3. Market Revenue and Forecast, by Mode
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Services
11.4.5.2. Market Revenue and Forecast, by Molecule
11.4.5.3. Market Revenue and Forecast, by Mode
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Services
11.4.6.2. Market Revenue and Forecast, by Molecule
11.4.6.3. Market Revenue and Forecast, by Mode
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Services
11.4.7.2. Market Revenue and Forecast, by Molecule
11.4.7.3. Market Revenue and Forecast, by Mode
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Services
11.5.2. Market Revenue and Forecast, by Molecule
11.5.3. Market Revenue and Forecast, by Mode
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Services
11.5.4.2. Market Revenue and Forecast, by Molecule
11.5.4.3. Market Revenue and Forecast, by Mode
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Services
11.5.5.2. Market Revenue and Forecast, by Molecule
11.5.5.3. Market Revenue and Forecast, by Mode
12.1. Catalent, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Charles River Laboratories International, Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Almac Group
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eurofins Scientific
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Lucideon Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Intertek Group Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Alcami Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Element Materials Technology
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Q1 Scientific
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. BioLife Solutions
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
